Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Mohammed Snober, Richard Syzdlo, PhD, Jane Apperley, MB ChB MD, Aristeidis Chaidos, MD PhD, Edward Kanfer, PhD, Dragana Milojkovic, MBBS, PhD, Eduardo Olavarria, MD PhD, Renuka Palanicawandar, MD MRCP, FRCPath, Jiri Pavlu, MD MRCP, FRCPath, Jeannie F Todd, PhD, Nina Salooja, MD

Blood (2018) 132 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2018-99-114229

Published: 2018

Journal Articles

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Denis-Claude Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD, Philippe Lewalle, MD, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva-Maria Wagner, MD, Halvard Bonig, MD, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2018) 132 (Supplement 1): 120.

https://doi.org/10.1182/blood-2018-99-119086

Published: 2018

Journal Articles

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

Andrew James Innes, PhD FRCPath, MRCP, Philippa Woolley, MRCP, MBBS, Richard Szydlo, PhD, Sara Lozano, Fiona Fernando, MBChB, Divya Bansal, Renuka Palanicawandar, MD MRCP,FRCPath, Elisabet Nadal-Melsio, MD, Eva Yebra-Fernandez, MD, Jane Apperley, MB ChB MD, Eduardo Olavarria, MD PhD, Jiri Pavlu, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2018-99-117311

Published: 2018

Journal Articles

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Philippa Woolley, MRCP, MBBS, David Slade, Richard Syzdlo, PhD, George Nasry Nesr, MB BCh, Simone Claudiani, MD, Irene Caballes, RN, Fiona Fernando, MBChB, Jiri Pavlu, MD MRCP, FRCPath, Renuka Palani, MD, Edward Kanfer, FRCP, Eduardo Olavarria, MD PhD, Dragana Milojkovic, MBBS, PhD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 5746.

https://doi.org/10.1182/blood-2018-99-114420

Published: 2018

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Sandra Cohen, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Eduardo Olavarria, MD PhD, Dominik Selleslag, MD, Manfred Rudiger, Jurjen Velthuis, PhD, Karen Reitsma, PhD, Lisya Gerez, Jeroen Rovers, MDPhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2015) 126 (23): 4391.

https://doi.org/10.1182/blood.V126.23.4391.4391

Published: 2015

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Blood (2015) 126 (23): 4403.

https://doi.org/10.1182/blood.V126.23.4403.4403

Published: 2015

Journal Articles

The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes

Blood (2015) 126 (23): 3223.

https://doi.org/10.1182/blood.V126.23.3223.3223

Published: 2015

Journal Articles

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Franck E. Nicolini, MD PhD, Grzegorz W. Basak, MD PhD, Dong-Wook Kim, MD PhD, Eduardo Olavarria, MD PhD, Javier Pinilla-Ibarz, MD PhD, Jane F. Apperley, MD, Timothy P. Hughes, MD, Dietger Niederwieser, MD, Michael J. Mauro, MD, Charles Chuah, MD PhD, Andreas Hochhaus, MD, Giovanni Martinelli, MD PhD, Maral DerSarkissian, PhD, Andrew Kageleiry, BS, Mo Yang, PhD, Hui Huang, MBA, PhD, Lisa J. McGarry, MPH, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 480.

https://doi.org/10.1182/blood.V126.23.480.480

Published: 2015

Journal Articles

High Mortality Associated with Neurological Complications after Allogeneic Stem Cell Transplantation

Sara Lozano, MD, Amaya Zabalza, Intza Aoiz, Mohamed Hamdi Djatri, Pedro Arregui, MD, Ivan Quispe, MD, Mari Cruz Montoya, Montserrat Alvarellos, Patricia Garcia Ramirez, Ana Gorosquieta, Katy Perez Equiza, Eduardo Olavarria, MD PhD

Blood (2014) 124 (21): 5843.

https://doi.org/10.1182/blood.V124.21.5843.5843

Published: 2014

Journal Articles

Alemtuzumab As Pre-Conditioning Is Safe and Feasible in Patients with T-Cell Lymphoid Neoplasms Undergoing Allogeneic Stem Cell Transplantation

Sara Lozano, MD, Amaya Zabalza, Intza Aoiz, Mohamed Hamdi Djatri, Pedro Arregui, MD, Ivan Quispe, MD, Mari Cruz Montoya, Montserrat Alvarellos, Patricia Garcia Ramirez, Katy Perez Equiza, Ana Gorosquieta, Eduardo Olavarria, MD PhD

Blood (2014) 124 (21): 5863.

https://doi.org/10.1182/blood.V124.21.5863.5863

Published: 2014

Journal Articles

C-Reactive Protein on Admission Predicts Transplant-Related Mortality in Recipients of Allogeneic Stem Cell Transplant.

Andrea K. Kew, MD, Richard M. Szydlo, PhD, Eduardo Olavarria, MD, PhD, John M. Goldman, DM, Jane F. Apperley, MD

Blood (2007) 110 (11): 3005.

https://doi.org/10.1182/blood.V110.11.3005.3005

Published: 2007

Journal Articles

Direct Adoptive Transfer of Cytomegalovirus-Specific CTL from Unrelated Donors to Stem Cell Transplant Patients Following Selection by HLA-Peptide Tetramers.

Mark Cobbold, MD, PhD, Persis Amrolia, MD, PhD, Prem Mahendra, MD, PhD, Colin Steward, MD, PhD, Eduardo Olavarria, MD, PhD, Julie Arrazi, Dorothy McDonald, PhD, Sudhir Tauro, MD, PhD, John Goldman, MD, PhD, Charles Craddock, MD, PhD, Paul Moss, MD, PhD

Blood (2004) 104 (11): 155.

https://doi.org/10.1182/blood.V104.11.155.155

Published: 2004

NARROW

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

High Mortality Associated with Neurological Complications after Allogeneic Stem Cell Transplantation

Alemtuzumab As Pre-Conditioning Is Safe and Feasible in Patients with T-Cell Lymphoid Neoplasms Undergoing Allogeneic Stem Cell Transplantation

C-Reactive Protein on Admission Predicts Transplant-Related Mortality in Recipients of Allogeneic Stem Cell Transplant.

Direct Adoptive Transfer of Cytomegalovirus-Specific CTL from Unrelated Donors to Stem Cell Transplant Patients Following Selection by HLA-Peptide Tetramers.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only